KSQ Therapeutics Appoints John Lepore, M.D., to its Board of Directors
22. Oktober 2024 07:00 ET
|
KSQ
KSQ Therapeutics Appoints John Lepore, M.D., to its Board of Directors
KSQ Therapeutics Appoints Anna Truppel-Hartmann, M.D., as Chief Medical Officer
08. Oktober 2024 07:00 ET
|
KSQ
KSQ Therapeutics Appoints Anna Truppel-Hartmann, M.D., as Chief Medical Officer
KSQ Therapeutics Announces FDA Clearance of IND Application for KSQ-004EX, a CRISPR/Cas9 Engineered Tumor-Infiltrating Lymphocyte (eTIL®) Therapy
24. September 2024 07:00 ET
|
KSQ
KSQ Therapeutics Announces FDA Clearance of IND Application for KSQ-004EX, a CRISPR/Cas9 Engineered Tumor-Infiltrating Lymphocyte (eTIL®) Therapy
KSQ Therapeutics Announces First Patient Dosed in Clinical Development Program for KSQ-001EX, a CRISPR/Cas9 Engineered Tumor Infiltrating Lymphocyte (eTIL®) Therapy
12. Juni 2024 07:00 ET
|
KSQ
KSQ Therapeutics Announces First Patient Dosed in Clinical Development Program for KSQ-001EX, a CRISPR/Cas9 Engineered eTIL® Therapy
Tumor Infiltrating Lymphocyte TIL Therapy Market Size Clinical Trials Companies Insight
21. März 2023 08:02 ET
|
KuicK Research
Delhi, March 21, 2023 (GLOBE NEWSWIRE) -- Tumor infiltrating lymphocyte (TIL) therapy is an emerging field in cancer immunotherapy. As researchers all over the world are conducting clinical trials...
Lyell Immunopharma Announces FDA Clearance of its IND for LYL845, a TIL Product Candidate Enhanced with its Novel Epigenetic Reprogramming Technology for Solid Tumors
06. Oktober 2022 16:05 ET
|
Lyell Immunopharma, Inc
Autologous TIL therapy enhanced with Lyell’s Epi-R™ reprogramming technology designed to create polyclonal T cell populations with properties of durable stemness and improved functionPhase 1 trial to...